I was hoping to keep COVID-19 out of this piece, but new things keep flooding in, and I can’t totally ignore them. However, I’ll save them to the end of the story. They are both “good news,” more or less, and I like to leave you with a bit of cheer, when possible. Sleep and […]
Articles
As I write this, both the US and the world are seeing an upsurge in COVID-19. There has been a 46% spike in hospitalized patients, and in the past seven days more than a half-million more Americans have contracted the coronavirus. According to the Johns Hopkins dashboard that tracks COVID-19 cases all over the world, […]
I’ve gotten a few questions about the latest Technology Profits Confidential (currently $79/yr) tease from Ray Blanco, so although it’s a few weeks old now, and started circulating right in the heat of the first coronavirus downturn in mid-March, I thought I’d take a look today. It is still a current ad, I got it […]
This particular bit of news leaves your friend Doc Gumshoe shaking his head in puzzlement. To wit, in the US it is expected that there will be a substantial shortage of physicians in the upcoming years. The American Association of Medical Colleges predicts that this shortage may reach about 122,000 physicians by the year […]
[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]
[Ed note: Here is our latest piece from “Doc Gumshoe”, who is a medical writer (not a doctor) who shares his wisdom with us at Stock Gumshoe a couple times a month. He does not typically write specifically about investments, but does write about publicly traded companies and their drugs, and has agreed to our trading […]
Newsletter copywriters are no different from other marketers: they will do whatever it takes to get attention by playing off of something or someone that has celebrity or notoriety. In the past that’s meant implying that some big celebrity investor has a connection to a “secret” stock or technique, or that someone high up in […]
This article originally appeared on July 22, 2015, and the bulk of it has not been updated or revised since. The meat of the ad is essentially the same, and if Lichtenfeld really “bet his paycheck” on this stock (which was and is Alnylam) on July 22 he’s so far lost about 65% of that […]
Today I’ve been asked about another urgent pitch from the Bonner & Partners crowd, and it’s so similar to one of their past ads that I thought I’d throw out the quick answer for you and let you chew on it a bit. The basic spiel is that there’s an IPO scheduled for Friday, and […]
Cancer Care: Current Directions[ed note: Michael Jorrin, who I like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who shares his thoughts with us from time to time, generally on non-financial topics in health and medicine (as today, though, he mentions a couple publicly traded companies). His words and opinions are his own.] The […]
[ed note: Dr. KSS is a paid contributor to Stock Gumshoe who writes about biotech stocks for (and discusses them with) the Irregulars. He chooses his own topics, and his words and opinions are his alone. Enjoy!] Greetings fellow Irregulars! You’ve all been waiting for it….our first-ever annual ceremony in which we look back on […]
[ed note: Michael Jorrin, who we like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who writes non-investment articles about medicine and health topics for us once or twice a month. As with all of our guest contributors and columnists, he chooses his own topics and his words are his alone] […]
[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Any discussion of cholesterol immediately turns Brobdingnagian, such are the extremes in question. Statins, which lower LDL cholesterol, are bombastically the best-selling drugs of all […]
[Ed note: Here is our latest piece from “Doc Gumshoe”, who is a medical writer (not a doctor) who shares his wisdom with us at Stock Gumshoe a couple times a month. As always, Michael’s words and opinions are his own.] Lots of analysts and prognosticators give these cholesterol-lowering agents a big thumbs up. The […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
KEYS 1 year stock price change: + 81.78%; BMRN: +6.72%; REGN: +9.22%; VRTX: -0.22%...
4 stocks recommended in special reports from March 2021: KEYS, BMRN, REGN, and VRTX. I am a subscriber to the Near Futu...
JB's has only four biotech recommendations on his $49/yr service: they are ILMN and REGN, BMRN, and VRTX. The only one t...
More to the point of the stocks - glad I didn’t give them any money since I’m already invested in three of the four ...
Ray has pushed INO and GILD multiple times over the prior month but no mention of REGN in this publication....
Top 3 Coronavirus stocks Regeneron Pharma (REGN) BioNtec (BNTX) MaAerns Inc. (MRNA) Thank:-:You FRANK8MORRISS frankeight...
Trump drug pricing speech tomorrow 2PM will focus on Medicare Part B drugs --> $IBB $XBI $REGN TY https://twitter.com/A...
$OPTH long BTW, the approval of a "me-too" drug for wet AMD, Eylea, gave us Regeneron, $REGN. Just sayin....... eyed...
$OPHT NP with itchy trigger finger So little mad money, but so many, many binary situations in biotech to trip over! ...
CRISPR/Cas9 company Intellia getting set for 140 million IPO with a 75 million partnership intact with Regeneron (REGN) ...
Morgan Stanley has 44 stocks on takeover target radar, including 3 biopharma - Celgene (CELG), Regeneron (REGN) and Ale...